非糖尿病绝经后女性胰岛素抵抗与骨代谢的相关性研究
PDF下载 (319)林伊荷,刘 芳,牛亚丹,李冬梅,李宇宁,徐冉行,陈青山,徐雷艇.非糖尿病绝经后女性胰岛素抵抗与骨代谢的相关性研究[J].宁波大学学报(理工版),2022,35(3):63-69.DOI:
LIN Yihe,LIU Fang,NIU Yadan,LI Dongmei,LI Yuning,XU Ranxing,CHEN Qingshan,XU Leiting.Association between insulin resistance and bone metabolism in non-diabetic postmenopausal women[J].Journal of Ningbo University(Natural Science & Engineering Edition),2022,35(3):63-69.DOI:
| Title: | Association between insulin resistance and bone metabolism in non-diabetic postmenopausal women |
| 作者: | 林伊荷, 刘 芳, 牛亚丹, 李冬梅, 李宇宁, 徐冉行, 陈青山, 徐雷艇 |
| Author(s): | LIN Yihe, LIU Fang, NIU Yadan, LI Dongmei, LI Yuning, XU Ranxing, CHEN Qingshan, XU Leiting |
| 关键词: | 胰岛素抵抗; 骨质疏松症; 骨密度; 骨转换标志物 |
| Keywords: | insulin resistance; osteoporosis; bone mineral density; bone turnover markers |
| 分类号: | R592 |
| 文献标识码: | A |
| 摘要: | 为探讨胰岛素抵抗与骨代谢之间的相互关系, 采用双能X线吸收仪测量了262名非糖尿病绝经后女性腰椎L1-4和股骨颈(femoral neck, FN)的骨密度(bone mineral density, BMD), 并检测了其外周血骨转换标志物和糖代谢指标以及雌激素水平. 结果发现胰岛素和稳态模型评估的胰岛素抵抗(homeostasis model assessment of insulin resistance, HOMA-IR)指数与L1-4和FN BMD均呈正相关(P<0.01), 但在控制体重指数(body mass index, BMI)与游离雌二醇(free estradiol, FE2)水平后相关性均消失(P>0.05); 高HOMA-IR组(OR=0.59, P=0.003)和中HOMA-IR组(OR=0.52, P=0.044)的骨质疏松症患病风险显著低于低HOMA-IR组, 但校正BMI和FE2后差异消失(OR=0.81, P=0.263和OR=0.68, P=0.268); 高HOMA-IR组骨钙素水平显著低于低HOMA-IR组(P=0.001), 即使校正BMI和FE2后差异仍有统计学意义(P=0.027). 因此, 胰岛素抵抗不是非糖尿病绝经后女性骨质疏松症的独立保护或风险因素, 而骨钙素可能通过影响外周组织胰岛素敏感性参与糖代谢. |
| Abstract: | The current study was aimed to investigate the relationship between insulin (INS) resistance and bone metabolism, the bone mineral density (BMD) of lumbar spine L1-4 and femoral neck (FN) in 262 non-diabetic postmenopausal women who were diagnosed by dual-energy X-ray absorptiometry. Bone turnover markers, glucose metabolism and estrogen levels in peripheral blood were measured. The results showed that INS and homeostasis model assessment of insulin resistance (HOMA-IR) index were positively correlated with L1-4 and FN BMD (P<0.01). However, the correlation did not hold after controlling body mass index (BMI) and free estradiol (FE2) levels (P>0.05). OP risk in the high HOMA-IR group (OR=0.59, P=0.003) and middle HOMA- IR group (OR=0.52, P=0.044) was significantly lower than that in the low HOMA-IR group. However, the difference was no longer existing after adjusting for BMI and FE2 (OR=0.81, P=0.263 and OR=0.68, P=0.268, respectively). The osteocalcin (OCN) level in the high HOMA-IR group was significantly lower than that in the low HOMA-IR group (P=0.001) and the difference was still statistically significant even after adjusting for BMI and FE2 (P=0.027). Therefore, INS resistance was not an independent protective or risk factor for OP in non-diabetic postmenopausal women. OCN may be involved in glucose metabolism by influencing peripheral tissue INS sensitivity. |
| 参考文献 /References: | [1] [1] Anam A K, Insogna K. Update on osteoporosis screening and management[J]. The Medical Clinics of North America, 2021, 105(6):1117-1134. [2] [2] Xu L T, Wang Q, Wang Q J, et al. Concerted actions of insulin-like growth factor 1, testosterone, and estradiol on peripubertal bone growth: a 7-year longitudinal study[J]. Journal of Bone and Mineral Research, 2011, 26(9):2204- 2211. [3] [3] Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis[J]. The American Journal of Medicine, 1993, 94(6):646-650. [4] [4] Lee S H, Park S Y, Choi C S. Insulin resistance: From mechanisms to therapeutic strategies[J]. Diabetes & Metabolism Journal, 2022, 46(1):15-37. [5] [5] Kahn S E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes[J]. Diabetologia, 2003, 46(1):3-19. [6] [6] Si Y, Wang C, Guo Y, et al. Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the chinese mainland: a systematic review and meta-analysis[J]. Iranian Journal of Public Health, 2019, 48(7):1203-1214. [7] [7] Sato M, Ye W, Sugihara T, et al. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: Retrospective analysis of a hospital claims database[J]. BMC Musculoskeletal Disorders, 2016, 17(1):489. [8] [8] R?kel A, Sheehy O, Rahme E, et al. Osteoporosis among patients with type 1 and type 2 diabetes[J]. Diabetes & Metabolism, 2008, 34(3):193-205. [9] [9] Motyl K J, McCabe L R, Schwartz A V. Bone and glucose metabolism: A two-way street[J]. Archives of Biochemistry and Biophysics, 2010, 503(1):2-10. [10] [10] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5):413-444. [11] [11] Wang Q J, Nicholson P H F, Suuriniemi M, et al. Relationship of sex hormones to bone geometric properties and mineral density in early pubertal girls[J]. The Journal of Clinical Endocrinology & Metabolism, 2004, 89(4):1698-1703. [12] [12] Kim S H, Choi Y J, Ahn M B, et al. Associations between sclerostin and anthropometric and metabolic parameters in children and adolescents[J]. Children, 2021, 8(9):788. [13] [13] Al-Qarakhli A M A, Yusop N, Waddington R J, et al. Effects of high glucose conditions on the expansion and differentiation capabilities of mesenchymal stromal cells derived from rat endosteal niche[J]. BMC Molecular and Cell Biology, 2019, 20(1):51. [14] [14] Freude T, Braun K F, Haug A, et al. Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-β[J]. Journal of Molecular Medicine (Berlin, Germany), 2012, 90(11):1257-1266. [15] [15] Araújo R, Martin V, Ferreira R, et al. A new ex vivo model of the bone tissue response to the hyperglycemic environment - The embryonic chicken femur organotypic culture in high glucose conditions[J]. Bone, 2022, 158: 116355. [16] [16] Wang X, Feng Z, Li J, et al. High glucose induces autophagy of MC3T3-E1 cells via ROS-AKT-mTOR axis [J]. Molecular and Cellular Endocrinology, 2016, 429:62- 72. [17] [17] Qu B, Gong K, Yang H, et al. SIRT1 suppresses high glucose and palmitate-induced osteoclast differentiation via deacetylating p66Shc[J]. Molecular and Cellular Endocrinology, 2018, 474:97-104. [18] [18] Abrahamsen B, Rohold A, Henriksen J E, et al. Correlations between insulin sensitivity and bone mineral density in non-diabetic men[J]. Diabetic Medicine, 2000, 17(2):124-129. [19] [19] Fulzele K, Riddle R C, DiGirolamo D J, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition[J]. Cell, 2010, 142(2): 309-319. [20] [20] Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: Basic biology[J]. Diabetologia, 2017, 60(7):1163- 1169. [21] [21] Fu C, Zhang X, Ye F, et al. High insulin levels in KK-Ay diabetic mice cause increased cortical bone mass and impaired trabecular micro-structure[J]. International Journal of Molecular Sciences, 2015, 16(4):8213-8226. [22] [22] Thrailkill K M, Lumpkin C K Jr, Bunn R C, et al. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues[J]. American Journal of Physiology Endocrinology and Metabolism, 2005, 289(5):E735- E745. [23] [23] Janghorbani M, van Dam R M, Willett W C, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture[J]. American Journal of Epidemiology, 2007, 166(5):495-505. [24] [24] Huang S, Kaw M, Harris M T, et al. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1[J]. Bone, 2010, 46(4):1138- 1145. [25] [25] Shanbhogue V V, Finkelstein J S, Bouxsein M L, et al. Association between insulin resistance and bone structure in nondiabetic postmenopausal women[J]. The Journal of Clinical Endocrinology & Metabolism, 2016, 101(8): 3114-3122. [26] [26] Verroken C, Zmierczak H G, Goemaere S, et al. Insulin resistance is associated with smaller cortical bone size in nondiabetic men at the age of peak bone mass[J]. The Journal of Clinical Endocrinology & Metabolism, 2017, 102(6):1807-1815. [27] [27] Dennison E M, Syddall H E, Aihie Sayer A, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? [J]. Diabetologia, 2004, 47(11):1963-1968. [28] [28] Wang L, You X, Zhang L, et al. Mechanical regulation of bone remodeling[J]. Bone Research, 2022, 10:16. [29] [29] Aguirre L, Napoli N, Waters D, et al. Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults[J]. The Journal of Clinical Endocrinology & Metabolism, 2014, 99(9):3290- 3297. [30] [30] Sanches C P, Vianna A G D, Barreto F C. The impact of type 2 diabetes on bone metabolism[J]. Diabetology & Metabolic Syndrome, 2017, 9:85. [31] [31] Zhou R, Guo Q, Xiao Y, et al. Endocrine role of bone in the regulation of energy metabolism[J]. Bone Research, 2021, 9:25. [32] [32] Fernandes T A P, Gon?alves L M L, Brito J A A. Relationships between bone turnover and energy metabolism[J]. Journal of Diabetes Research, 2017, 2017: 9021314. [33] [33] Diegel C R, Hann S, Ayturk U M, et al. An osteocalcin-deficient mouse strain without endocrine abnormalities[J]. PLoS Genetics, 2020, 16(5):e1008361. [34] [34] Winhofer Y, Handisurya A, Tura A, et al. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus[J]. Diabetes Care, 2010, 33(1):139-143. [35] [35] Jiajue R, Liu S, Pei Y, et al. Associations between osteocalcin, calciotropic hormones, and energy meta- bolism in a cohort of Chinese postmenopausal women: Peking vertebral fracture study[J]. International Journal of Endocrinology, 2021, 2021:5585018. [36] [36] Shea M K, Gundberg C M, Meigs J B, et al. γ-Carboxylation of osteocalcin and insulin resistance in older men and women[J]. The American Journal of Clinical Nutrition, 2009, 90(5):1230-1235. [37] [37] Starup-Linde J, Westberg-Rasmussen S, Lykkeboe S, et al. Glucose tolerance tests and osteocalcin responses in healthy people[J]. Frontiers in Endocrinology, 2018, 9:356. [38] [38] Lu C, Ivaska K K, Alen M, et al. Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women[J]. The Journal of Clinical Endocrinology & Metabolism, 2012, 97(11):4106-4114. |
| 备注/Memo: | 收稿日期:2022-02-27.宁波大学学报（理工版）网址:http://journallg.nbu.edu.cn/ 基金项目:浙江省自然科学基金（LY16H070001）. 第一作者:林伊荷（1995－）,女,浙江舟山人,在读硕士研究生,主要研究方向:骨质疏松症队列研究.E-mail:5321798@qq.com *通信作者:徐雷艇（1973－）,男,浙江舟山人,博士/副研究员,主要研究方向:骨质疏松症人群与基础研究.E-mail:xuleiting@nbu.edu.cn 宁波大学学报（理工版）网址：http://journallg.nbu.edu.cn/ |
